Substituted azole aromatic heterocycles as inhibitors of...

Details Substituted azole aromatic heterocycles as inhibitors of... Substituted azole aromatic heterocycles as inhibitors of...

2007-07-18

2010-02-23

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S406000, C548S248000, C548S364100

Reexamination Certificate

active

07666888

ABSTRACT:
Compounds of formula I and IV are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorder:wherein the variables A-B, R1, R2, m, and Q are described herein.

REFERENCES:
patent: 4765539 (1988-08-01), Noakes et al.
patent: 4962885 (1990-10-01), Coffee
patent: 5112598 (1992-05-01), Biesalski
patent: 5494911 (1996-02-01), Bartlett et al.
patent: 5532259 (1996-07-01), Bartlett et al.
patent: 5556611 (1996-09-01), Biesalski
patent: 5912114 (1999-06-01), Hutchinson et al.
patent: 5950619 (1999-09-01), van der Linden et al.
patent: 5954047 (1999-09-01), Armer et al.
patent: 5970974 (1999-10-01), van der Linden et al.
patent: 6096770 (2000-08-01), Lennox et al.
patent: 6180796 (2001-01-01), Morohashi et al.
patent: 6262098 (2001-07-01), Huebner et al.
patent: 6387920 (2002-05-01), Huebner et al.
patent: 6458960 (2002-10-01), Morohashi et al.
patent: 6727273 (2004-04-01), Huebner et al.
patent: 6743815 (2004-06-01), Huebner et al.
patent: 6869953 (2005-03-01), Haag et al.
patent: 6869969 (2005-03-01), Huebner et al.
patent: 6946462 (2005-09-01), Haag et al.
patent: 2002/0137769 (2002-09-01), Lee et al.
patent: 2004/0010005 (2004-01-01), Barnett et al.
patent: 2004/0097734 (2004-05-01), Gerlach et al.
patent: 2004/0180881 (2004-09-01), Berta et al.
patent: 2005/0096376 (2005-05-01), Sundermann et al.
patent: 2006/0223852 (2006-10-01), Gillespie et al.
patent: 2006/0241121 (2006-10-01), Greenlee et al.
patent: 2007/0249631 (2007-10-01), Oberboersch et al.
patent: 0 558 258 (1993-09-01), None
patent: 0 569 193 (1993-11-01), None
patent: 0 902 288 (1999-03-01), None
patent: 1 069 114 (2001-01-01), None
patent: 1 236 726 (2002-09-01), None
patent: WO 94/12285 (1994-06-01), None
patent: WO 94/14543 (1994-07-01), None
patent: WO 95/26234 (1995-10-01), None
patent: WO 95/26235 (1995-10-01), None
patent: WO 95/32807 (1995-12-01), None
patent: WO 97/39745 (1997-10-01), None
patent: WO 99/07670 (1999-02-01), None
patent: WO 99/47196 (1999-09-01), None
patent: WO 00/56729 (2000-09-01), None
patent: WO 01/16116 (2001-03-01), None
patent: WO 03/015780 (2003-02-01), None
patent: WO 03/088908 (2003-10-01), None
patent: WO 2004/050087 (2004-06-01), None
patent: WO 2004/054974 (2004-07-01), None
patent: WO 94/24095 (2004-10-01), None
patent: WO 2004/100946 (2004-11-01), None
patent: WO 2005/105759 (2005-11-01), None
Vippagunta et al., Crystalline solids, 2001, Advanced Drug Delivery Reviews, 48, pp. 3 and 18.
Alberola, Angel, et al., Comparative Reactivity of 3-Methyl-5- Penysisoxazole and 3-Methyl-a5- Penylisothiazole Against Electrophilic Compounds,Journal of Heterocyclic Chemistry, 1995, 32(2), pp. 537-541.
Albiston, A.L., et al., “Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme”,Mol Cell Endocrinol, 1994, 105(2):R11-7.
Anstead, G.M, “Steroids, retinoids, and wound healing”,Adv Wound Care, 1998, 11(6), pp. 277-285.
Basu, U., et al., “Search for New Analeptic. I. Synthesis of Cyclotetra-Methyleneisoxazole”,J. Indian Chem. Soc., 1946, 23, pp. 189-192.
Beer, H.D., et al., “Glucocorticoid-regulated gene expression during cutaneous wound repair”Vitam Horm, 2000, 59, pp. 217-239.
Bellows, C.G., et al.,Bone23. 1998, : pp. 119-125.
Betti, M., et al., “The Isomerizm of Isoxazolecarboxylic Acids”,Gazzeta Chimica Italiana, 1921, 51(II), pp. 229-239.
Billaudel, B. and B.C.J. Sutter (1979) Horm. Metab. Res. 11: pp. 555-560.
Brough, Paul A. et al.,Bioorganic&Medicinal Chemistry Letters, 2005, 15(23), pp. 5197-5201.
Bujalska, I.J., S. Kumar, and P.M. Stewart (1997) Lancet 349: pp. 1210-1213.
Burger's Medicinal Chemistry and Drug Discovery 6thed. (Donald J. Abrahamed., 2001, Wiley).
Cardonna, C., et al., “Synthesis and Bacteriostatic Activity of Hydroxamic Acid Derivative of Isoxazole”,Farmaco, Edizione Scientifica, 1960, 15, pp. 647-654.
Carenzi, A., et al., “New Isoxazole Derivatives Provided With Antihypertensive Activity”,Arzneimittel-Forschung, 1989, 39(6), pp. 642-646.
Cheng, Y.C.; Prushoff, W.H.Biochem. Pharmacol. 1973, 22, pp. 3099-3108.
Cooper, M.S. et al.,Bone27, 2000, pp. 375-381.
Cooper, M.S., et al., “11beta-hydroxysteroid dehydrogenase in human fibroblasts: expression and regulation depends on tissue of origin”,ENDO 2003 Abstracts 2003.
Dahl et al., Poster 524 atAmerican Association of Cancer Research, San Francisco, Calif., Apr. 1-5, 2000.
Dains, F.B. et al,Journal of the American Chemical Society, 1921, 43, pp. 1200-1202.
Dains, F.B., et al., “Reactions of the Formamidines. III. Synthesis of Isoxazolone, Isoxazole, Cuampacetoc and Benzoylacetic Acid Derivatives”,Journal of the American Chemical Society, 1913, 35, pp. 959-970.
Davani, B. et al. (2000) J. Biol. Chem. Nov. 10, 2000; 275(45): pp. 34841-34844.
de Quervain, D.J. et al.,Nature, 1998, 394: pp. 787-790.
Design and Application of Prodrugs(H. Bundgaarded., 1985, Harwood Academic Publishers Gmfh).
Diethelm, A.G., “Surgical management of complications of steroid therapy”,Ann Surg, 1977, 185(3): pp. 251-263.
During et al.,Ann. Neurol., 1989,25, p. 351.
Engelke et al., Poster 342 atAmerican Association of Cancer Research, San Francisco, Calif., Apr. 1-5, 2000.
English et al., J. Clin. Endocrinol. Metab. 1999, 84: pp. 2080-2085.
Fossa, Paola, et al., “5-Substituted 4-Isoxazolecarboxamides with Platelet Antiaggregating and Other Activities”,Ist, Sci. Farm., Univ. Genova, Genoa, I-16132, Italy Farmaco, 1991, 46(6), pp. 789-802.
Fraser, R. et al. (1999) Hypertension 33: pp. 1364-1368.
Frey, F.J., et al, “Pharmacology of 11 beta-hydroxysteroid dehydrogenase”,Steroids, 1994, 59(2):, pp. 74-79.
Ganong, W.F. Review of Medical Physiology. Eighteenth edition ed. Stamford, Connecticut: Appleton & Lange; 1997.
Ge et al., Biology of Reproduction 1999, 60: pp. 855-860.
Geissler et al., Nat. Genet. 1994, 7: pp. 34-39.
Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115 (1984).
Halleux, C.M. et al. (1999) J. Clin. Endocrinol. Metab. 84: pp. 4097-4105.
Hammami, M.M., et al., “Regulation of 11 beta-hydroxysteroid dehydrogenase activity in human skin fibroblasts: enzymatic modulation of glucocorticoid action”,J Clin Endocrinol Metab, 1991, 73(2), pp. 326-334.
Hamon, G.A., Hunt, T.K., Spencer, E.M. “In vivo effects of systemic insulin-like growth factor-I alone and complexed with insulin-like growth factor binding protein-3 on corticosteroid suppressed wounds”,Growth Regul,1993, 3(1), pp. 53-56.
Hanson, J.C. et al., “Derivatives of 6-Aminopenicillanic Acid”,Journal of the Chemical Society, 1965, November, pp. 5976-5983.
Houssay, B.A. (1942) Endocrinology 30: 884-892.
Howard et al., 1989,J. Neurosurg. 71, p. 105.
Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985).
J. Zhang, et al.Biochemistry, 44, 2005, pp. 6948-6957.
Jamieson et al. (2000) J. Endocrinol. 165: pp. 685-692.
Jens T. Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-380.
Kang, K.H., et al., “Solution-phase Combinatorial Synthesis of Isoxazolines and Isoxazoles Using [2+3] Cycloaddition Reaction of Nitrile Oxides”,Tetrahedron Letters, 2001, 42(6), pp. 1057-1060.
Kim, C.H., et al.,J. Endocrinol. 162, 1999, pp. 371-379.
Kitawaki et al., J. Clin. Endocrin. Metab., 2000, 85: pp. 1371-3292-3296.
Kotelevtsev, Y. et al., (1997) Proc. Natl. Acad. Sci. USA 94: pp. 14924-14929.
Laato, M., et al., “Epidermal growth factor (EGF) prevents methylprednisolone-induced inhibition of wound healing”,J Surg Res, 1989, 47(4):pp. 354-359.
Labrie et al., Mol. Cell. Endocrinol. 1991, 78: pp. C113-C118.
Langer,Science, 1990, 249, p. 1527.
Leszczynska, Barbara, et al., “Synthesis of 1-acyl-4-(5-Nitrofurfurylidenamino) Piperazines”,Acta Poloniae Pharmaceutica, 1981, 38(5), pp. 539-543.
Levy et al.,Science, 1985, 228, p. 190.
Long, C.D. and

Affiliated with

Also associated with

Rating

Substituted azole aromatic heterocycles as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted azole aromatic heterocycles as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted azole aromatic heterocycles as inhibitors of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4182530